Stock Earnings Negative sentiment towards GLUE reflected by a jump of 5.37% in short interest Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Monte Rosa
Analysts Viewpoint An Analysis of Monte Rosa Therapeutics Inc (GLUE)’s Potential Price Growth In a filing, Monte Rosa Therapeutics Inc revealed its Principal Accounting Officer Dunn Edmund unloaded Company’s shares for reported $9174.0